Mucus glycoprotein secretion

Mucus glycoprotein secretion is the physiological process by which specialized cells, such as goblet cells and submucosal glands, release high-molecular-weight mucins (primarily MUC5AC and MUC5B) into the extracellular space to form a protective mucus layer (Fahy JV, Dickey BF. N Engl J Med. 2010) [1]. This process is primarily mediated by the exocytosis of mucin-containing granules, a step regulated by intracellular signaling molecules like the MARCKS protein and calcium-dependent pathways (Davis CW, Dickey BF. Annu Rev Physiol. 2008) [2]. In healthy individuals, this secretion is vital for mucociliary clearance and defense against inhaled pathogens and environmental toxins (Rose MC, Voynow JA. Chest. 2006) [3]. However, in chronic respiratory diseases like asthma, COPD, and cystic fibrosis, mucus hypersecretion occurs, leading to airway plugging, inflammation, and reduced lung function (Evans CM, et al. Eur Respir J. 2009) [4]. Pharmacological strategies to manage this include the use of muscarinic antagonists to block neural triggers, corticosteroids to reduce mucin gene expression, and mucoregulatory drugs like carbocisteine that modulate the secretory process (Rogers DF. Paediatr Respir Rev. 2007) [5]. Emerging therapies also target the specific molecular machinery of exocytosis, such as MARCKS inhibitors, to prevent the excessive release of mucins without compromising basal defense mechanisms (Li Y, et al. Am J Respir Cell Mol Biol. 2001) [6].

Other names

Mucin secretionAirway mucus hypersecretionGoblet cell secretionMucus hypersecretion

Inhibition of mucin exocytosis via MARCKS protein modulation, blockade of muscarinic receptors on submucosal glands, and downregulation of MUC gene expression.